Like everyone in healthcare, clinical laboratories and pathology groups feel the financial squeeze. Shrinking budgets and decreasing prices for lab tests have made financial efficiencies a primary goal for nearly every medical lab in the United States, as noted in a recent article in Dark Daily. According to the article, labs shouldn’t only focus on low-hanging fruit like reducing staff overtime. They should also turn their attention to one of the biggest cost control opportunities: reducing errors.
The article notes that the “recurring cost of bad quality” is a fairly new concept in clinical laboratory operations. There have been attempts to address it, but unfortunately, much of the recurring cost of bad quality is nearly invisible. The problem is exacerbated by the fact that poor quality is all too often accepted as a normal consequence of lab tests.